https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3049)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3049)2013-06-03 00:00:002013-06-03 00:00:00Phase II study of dendritic cell vaccination combined with recombinant adenovirus-p53 in treatment for patients with advanced pancreatic carcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / Radiother Oncol 2013 Nov;109(2):188-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / Radiother Oncol 2013 Nov;109(2):188-932013-06-03 00:00:002013-06-03 00:00:00Re-irradiation and hyperthermia after surgery for recurrent breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-02 / Cancer Immunol. Immunother. 2013 Aug;62(8):1381-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-02 / Cancer Immunol. Immunother. 2013 Aug;62(8):1381-922013-06-02 00:00:002019-02-15 08:50:41Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-01 / J Clin Oncol 31, 2013 (suppl; abstr 3029)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-01 / J Clin Oncol 31, 2013 (suppl; abstr 3029)2013-06-01 00:00:002021-08-09 07:52:56Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study.
